We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Oncology and University Hospital Oslo Announce Genomic Profiling Collaboration
News

New Oncology and University Hospital Oslo Announce Genomic Profiling Collaboration

New Oncology and University Hospital Oslo Announce Genomic Profiling Collaboration
News

New Oncology and University Hospital Oslo Announce Genomic Profiling Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Oncology and University Hospital Oslo Announce Genomic Profiling Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

New Oncology and the University Hospital Oslo have announced that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies.

Under this agreement, New Oncology will apply its proprietary diagnostic platform ‘NEO’ that provides a fully informative molecular cancer profile from the smallest quantities of patient samples with short turn-around times. No financial details were disclosed.

“Dramatic responses to targeted therapies in patients with advanced solid tumours bearing drug-sensitizing mutations have shifted the paradigm of cancer treatment towards a comprehensive molecular characterization before initiation of treatment. The growing number of targeted drugs, different types of targetable genome alterations and the occurrence of resistance mechanisms are increasing challenges for clinical diagnostics. Technological and computational advances in the field of tumour diagnostics finally put us in the position to perform comprehensive, sensitive and fast analysis of all different types of genome alterations on routine tumour specimens. This is a pivotal step in matching the right patients with the right drugs, providing broad access to personalized cancer medicine to all patients” commented Prof. Roman Thomas, founder of New Oncology.

Advertisement